Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(3.86)
# 611
Out of 4,834 analysts
10
Total ratings
40%
Success rate
19.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $8.64 | +131.48% | 3 | Mar 18, 2025 | |
| VRNA Verona Pharma | Initiates: Buy | $68 | $69.53 | -2.20% | 1 | Jan 10, 2025 | |
| CING Cingulate | Initiates: Buy | $12 | $3.87 | +210.48% | 1 | Jan 10, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.84 | +734.33% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.81 | +286.74% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $8.12 | +257.14% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.40 | +614.29% | 1 | Dec 5, 2024 |
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $8.64
Upside: +131.48%
Verona Pharma
Jan 10, 2025
Initiates: Buy
Price Target: $68
Current: $69.53
Upside: -2.20%
Cingulate
Jan 10, 2025
Initiates: Buy
Price Target: $12
Current: $3.87
Upside: +210.48%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.84
Upside: +734.33%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.81
Upside: +286.74%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $8.12
Upside: +257.14%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%